# OnCo record mogamulizumab-atll-0761-009 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/mogamulizumab-atll-0761-009/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "mogamulizumab-atll-0761-009", "NCT01626664" ;
  schema:name "Study 0761-009: mogamulizumab against investigator's choice in relapsed adult T-cell leukaemia/lymphoma"@en ;
  schema:alternateName "0761-009"@en, "Phillips 2019"@en ;
  schema:description "Outside Japan, mogamulizumab produced confirmed responses in about one in ten people with relapsed adult T-cell leukaemia, more than chemotherapy did but far fewer than the Japanese study had suggested."@en ;
  schema:url <https://onco.cc/trials/mogamulizumab-atll-0761-009/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01626664>, <https://doi.org/10.3324/haematol.2018.205096> ;
  onco:status "mixed" ;
  onco:tag "lymphoma-evidence-entities" ;
  onco:phase "2" ;
  schema:startDate "2012-06" ;
  onco:cancers <https://onco.cc/cancers/adult-t-cell-leukaemia-lymphoma/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/ccr4/> ;
  onco:drugs <https://onco.cc/drugs/mogamulizumab/> ;
  onco:companies <https://onco.cc/companies/kyowa-kirin/> ;
  onco:terms <https://onco.cc/terms/orr/>, <https://onco.cc/terms/lymphoma-htlv-1/> ;
  onco:trials <https://onco.cc/trials/mogamulizumab-atll-phase-2-japan/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-mogamulizumab-vs-investigator-choice-atll-haematologica-2019/> .